Avalanche Biotechnologies, an early-stage biotech developing gene therapies for wet AMD and other ophthalmic diseases, filed on Monday with the SEC to raise up to $86 million in an initial public offering. The Menlo Park, CA-based company, which was founded in 2006, plans to list on the NASDAQ under the symbol AAVL. Avalanche Biotechnologies initially filed confidentially on May 30, 2014. Jefferies, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.
